Consolidated figures · ₹ crore
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 653 | 558 | 596 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 640 | |
| COGS | -8 | 13 | 187 | 172 | 157 | 205 | 262 | 253 | 230 | 200 | 280 |
| Gross profit | — | 545 | 409 | 284 | 387 | 420 | 399 | 207 | 329 | 360 | 359 |
| — | 483 | 323 | 416 | 356 | 343 | 413 | 305 | 349 | 385 | 364 | |
| — | 62 | 86 | -131 | 32 | 77 | -14 | -98 | -20 | -26 | -5 | |
| OPM % | — | 11.2% | 14.5% | -28.7% | 5.8% | 12.3% | -2.1% | -21.3% | -3.6% | -4.6% | -0.7% |
| Depreciation | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 | 33 |
| Interest | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 6 |
| 70 | 54 | 342 | 338 | 8 | 9 | 1,687 | 154 | 62 | 57 | 36 | |
| Profit before tax | — | — | — | — | -178 | -146 | 1,449 | 13 | 1 | -8 | -7 |
| Tax | 2 | -11 | 10 | 8 | 17 | 2 | 371 | 47 | 3 | 1 | -0 |
| Tax % | — | — | — | — | 9.4% | 1.4% | 25.6% | 363.7% | 201.4% | 9.7% | -2.9% |
| -18 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | -7 | |
| PAT margin % | -2.8% | -10.1% | -12.8% | 8.3% | -35.7% | -23.6% | 163% | -7.3% | -0.3% | -1.6% | -1.1% |
| EPS (₹) | — | — | — | — | -31.7 | -24.1 | 176 | -5.5 | -0.2 | -1.4 | -0.9 |
| EPS adjusted (₹) | -0.8 | -9.2 | -12.4 | 6.2 | -31.7 | -24.1 | 175.8 | -5.5 | -0.2 | -1.4 | -0.9 |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 449 | 397 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 | 829 |
| Minority interest | — | 12 | — | — | — | — | — | — | — | — | — |
| 1,059 | 975 | 736 | 116 | 617 | 735 | 34 | 20 | 21 | 22 | 24 | |
| 324 | 412 | 563 | 910 | 575 | 671 | 848 | 407 | 378 | 433 | 404 | |
| Total equity & liabilities | 1,854 | 1,803 | 1,608 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,262 |
| 1,071 | 1,053 | 948 | 806 | 657 | 609 | 622 | 600 | 569 | 551 | 560 | |
| CWIP | — | 11 | 8 | 8 | 10 | 21 | 5 | 28 | 75 | 94 | 100 |
| Investments | 9 | 8 | 7 | 5 | 6 | 0 | 5 | 13 | 53 | 19 | 26 |
| 775 | 730 | 645 | 556 | 718 | 548 | 1,127 | 630 | 544 | 626 | 577 | |
| Total assets | 1,854 | 1,803 | 1,608 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,262 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Vaccines | 410.25 | -26.84 | 870.14 | 302.02 | 568.12 | -4.72 |
| Formulations | 229.52 | 19.47 |
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 98 | 131 | 118 | 105 | -30 | 107 | -108 | -423 | -0 | -27 | 17 | |
| 23 | -26 | 55 | -5 | -35 | -48 | 1,283 | 430 | 10 | 65 | -40 | |
| -129 | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | -3 | -3 | -1 | |
| Net cash flow | -8 | — | — | — | 26 | 12 | -2 | -12 | 7 | 35 | -25 |
| Free cash flow | — | 107 | — | — | — | 85 | -121 | -464 | -78 | -78 | -37 |
| CFO / Operating profit % | — | 209.3% | 137% | — | -97.2% | 139.3% | — | — | — | — | — |
| 392.03 |
| 131.27 |
| 260.76 |
| 7.47 |
₹ crore by fiscal year